STA 36

Drug Profile

STA 36

Alternative Names: STA36

Latest Information Update: 22 Jul 2015

Price : $50

At a glance

  • Originator SunTen Phytotech
  • Developer Lumosa Therapeutics
  • Class Antiasthmatics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Allergic asthma

Most Recent Events

  • 22 Jul 2015 Discontinued - Phase-II for Allergic asthma (Adjuvant therapy) in Taiwan (unspecified route)
  • 31 Jan 2008 Taiwan Department of Health approves IND application for STA 36 in asthma
  • 12 Jul 2006 Phase-II clinical trials in Allergic asthma (Adjuvant therapy) in Taiwan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top